**Trader sentiment heavily favors “No” at 80.5% because the October 2024 research collaboration remains strictly an evaluation-stage agreement rather than a commercial license.** Under that deal, Eli Lilly received only a non-exclusive, worldwide license for internal R&D on applying Peptron’s ultrasonic spray-dried PLGA microsphere SmartDepot platform to select peptides, with any future commercial deal explicitly described as possible but not guaranteed. The original 14-month term was extended to a maximum of 24 months, placing the evaluation window through roughly October 2026, yet no binding technology-transfer or commercialization agreement has been announced in the intervening 20 months. Recent developments reinforce caution. Lilly’s June 2025 and 2026 expansions of its lipid-based injectable partnership with Camurus for overlapping therapeutic areas (including amylin agonists) triggered sharp share-price drops at Peptron, though the Korean firm reiterated that the platforms target different compounds and that SmartDepot evaluation continues on schedule. Preclinical data on PT403 (SmartDepot semaglutide) and safety signals have been shared, but these remain early-stage and have not triggered a commercial commitment. With only weeks left before the October 7 resolution and no reported progress toward a definitive license, capital-backed traders view a last-minute announcement as unlikely, producing the current strong “No” consensus.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$10,135 Vol.
$10,135 Vol.
7 oct 2026
$10,135 Vol.
$10,135 Vol.
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**Trader sentiment heavily favors “No” at 80.5% because the October 2024 research collaboration remains strictly an evaluation-stage agreement rather than a commercial license.** Under that deal, Eli Lilly received only a non-exclusive, worldwide license for internal R&D on applying Peptron’s ultrasonic spray-dried PLGA microsphere SmartDepot platform to select peptides, with any future commercial deal explicitly described as possible but not guaranteed. The original 14-month term was extended to a maximum of 24 months, placing the evaluation window through roughly October 2026, yet no binding technology-transfer or commercialization agreement has been announced in the intervening 20 months.
Recent developments reinforce caution. Lilly’s June 2025 and 2026 expansions of its lipid-based injectable partnership with Camurus for overlapping therapeutic areas (including amylin agonists) triggered sharp share-price drops at Peptron, though the Korean firm reiterated that the platforms target different compounds and that SmartDepot evaluation continues on schedule. Preclinical data on PT403 (SmartDepot semaglutide) and safety signals have been shared, but these remain early-stage and have not triggered a commercial commitment. With only weeks left before the October 7 resolution and no reported progress toward a definitive license, capital-backed traders view a last-minute announcement as unlikely, producing the current strong “No” consensus.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$10,135Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**Trader sentiment heavily favors “No” at 80.5% because the October 2024 research collaboration remains strictly an evaluation-stage agreement rather than a commercial license.** Under that deal, Eli Lilly received only a non-exclusive, worldwide license for internal R&D on applying Peptron’s ultrasonic spray-dried PLGA microsphere SmartDepot platform to select peptides, with any future commercial deal explicitly described as possible but not guaranteed. The original 14-month term was extended to a maximum of 24 months, placing the evaluation window through roughly October 2026, yet no binding technology-transfer or commercialization agreement has been announced in the intervening 20 months.
Recent developments reinforce caution. Lilly’s June 2025 and 2026 expansions of its lipid-based injectable partnership with Camurus for overlapping therapeutic areas (including amylin agonists) triggered sharp share-price drops at Peptron, though the Korean firm reiterated that the platforms target different compounds and that SmartDepot evaluation continues on schedule. Preclinical data on PT403 (SmartDepot semaglutide) and safety signals have been shared, but these remain early-stage and have not triggered a commercial commitment. With only weeks left before the October 7 resolution and no reported progress toward a definitive license, capital-backed traders view a last-minute announcement as unlikely, producing the current strong “No” consensus.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$10,135Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...**Trader sentiment heavily favors “No” at 80.5% because the October 2024 research collaboration remains strictly an evaluation-stage agreement rather than a commercial license.** Under that deal, Eli Lilly received only a non-exclusive, worldwide license for internal R&D on applying Peptron’s ultrasonic spray-dried PLGA microsphere SmartDepot platform to select peptides, with any future commercial deal explicitly described as possible but not guaranteed. The original 14-month term was extended to a maximum of 24 months, placing the evaluation window through roughly October 2026, yet no binding technology-transfer or commercialization agreement has been announced in the intervening 20 months. Recent developments reinforce caution. Lilly’s June 2025 and 2026 expansions of its lipid-based injectable partnership with Camurus for overlapping therapeutic areas (including amylin agonists) triggered sharp share-price drops at Peptron, though the Korean firm reiterated that the platforms target different compounds and that SmartDepot evaluation continues on schedule. Preclinical data on PT403 (SmartDepot semaglutide) and safety signals have been shared, but these remain early-stage and have not triggered a commercial commitment. With only weeks left before the October 7 resolution and no reported progress toward a definitive license, capital-backed traders view a last-minute announcement as unlikely, producing the current strong “No” consensus.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes